Doxifluridine in Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU) Containing Regimens

By Bajetta E.   Di Bartolomeo M.   Somma L.   Del Vecchio M.   Artale S.   Zunino F.   Bignami P.   Magnani E.   Buzzoni R.  

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 687-690

Elsevier

Access to resources Recommend Favorite

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

By Van Cutsem E.   Cunningham D.   Ten Bokkel Huinink W.W.   Punt C.J.A.   Alexopoulos C.G.   Dirix L.   Symann M.   Blijham G.H.   Cholet P.   Fillet G.   Van Groeningen C.   Vannetzel J.M.   Levi F.   Panagos G.   Unger C.   Wils J.   Cote C.   Blanc C.   Herait P.   Bleiberg H.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 54-59

Elsevier

Access to resources Recommend Favorite

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

By Benavides M.   García-Alfonso P.   Cobo M.   Muñoz-Martín A.   Gil-Calle S.   Carabantes F.   Villar E.   Graupera J.   Balcells M.   Pérez-Manga G.  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 255-262

Humana Press, Inc

Access to resources Recommend Favorite

Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer

By Fujishima Hiromitsu   Kikuchi Ikuo   Miyanaga Osamu   Ueda Akira   Baba Eishi   Mitsugi Kenji   Harada Mine   Nakano Shuji  

International Journal of Clinical Oncology, Vol. 9, Iss. 2, 2004-04 ,pp. : 92-97

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer

By Hütter G.   Szélenyi H.   Deckert P.   Keilholz U.   Thiel E.  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 2, 2004-08 ,pp. : 178-184

Springer Publishing Company

Access to resources Recommend Favorite